Lineage Cell Therapeutics, Inc. (LCTX) Operating Income (Loss) USD 2010 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2010 to 2024.
  • Lineage Cell Therapeutics, Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$6.66 M, a 0.29% decline year-over-year.
  • Lineage Cell Therapeutics, Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$24.8 M, a 8.72% decline year-over-year.
  • Lineage Cell Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$24.7 M, a 9.83% decline from 2022.
  • Lineage Cell Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$22.5 M, a 54.2% increase from 2021.
  • Lineage Cell Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$49.2 M, a 86.1% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$24.8 M -$6.66 M -$19 K -0.29% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$24.7 M -$6.36 M +$277 K +4.17% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$25 M -$6.71 M -$1.45 M -27.7% Jul 1, 2023 Sep 30, 2023 10-K 2024-03-07
Q2 2023 -$23.6 M -$5.02 M -$790 K -18.7% Apr 1, 2023 Jun 30, 2023 10-K 2024-03-07
Q1 2023 -$22.8 M -$6.64 M -$246 K -3.85% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$22.5 M -$6.64 M +$21.6 M +76.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 -$44.1 M -$5.25 M +$1.59 M +23.3% Jul 1, 2022 Sep 30, 2022 10-K 2024-03-07
Q2 2022 -$45.7 M -$4.23 M +$2.85 M +40.2% Apr 1, 2022 Jun 30, 2022 10-K 2024-03-07
Q1 2022 -$48.6 M -$6.4 M +$654 K +9.28% Jan 1, 2022 Mar 31, 2022 10-K 2024-03-07
Q4 2021 -$49.2 M -$28.2 M -$22.4 M -380% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 -$26.9 M -$6.84 M -$118 K -1.76% Jul 1, 2021 Sep 30, 2021 10-K 2023-03-09
Q2 2021 -$26.7 M -$7.08 M -$678 K -10.6% Apr 1, 2021 Jun 30, 2021 10-K 2023-03-09
Q1 2021 -$26.1 M -$7.05 M +$388 K +5.22% Jan 1, 2021 Mar 31, 2021 10-K 2023-03-09
Q4 2020 -$26.4 M -$5.88 M +$990 K +14.4% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$27.4 M -$6.73 M +$1.7 M +20.2% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-10
Q2 2020 -$29.1 M -$6.4 M +$4.42 M +40.8% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-10
Q1 2020 -$33.6 M -$7.44 M +$5.32 M +41.7% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-10
Q4 2019 -$38.9 M -$6.87 M +$3.24 M +32% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-11
Q3 2019 -$42.1 M -$8.42 M +$1.94 M +18.7% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-11
Q2 2019 -$44 M -$10.8 M -$1.68 M -18.3% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-11
Q1 2019 -$42.4 M -$12.8 M -$574 K -4.71% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-11
Q4 2018 -$41.8 M -$10.1 M -$544 K -5.69% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$41.3 M -$10.4 M -$844 K -8.87% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 -$40.4 M -$9.14 M -$580 K -6.77% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 -$39.8 M -$12.2 M -$925 K -8.21% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 -$38.9 M -$9.56 M +$1.69 M +15% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 -$40.6 M -$9.51 M +$42 K +0.44% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-14
Q2 2017 -$40.6 M -$8.56 M +$5.84 M +40.5% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-14
Q1 2017 -$46.5 M -$11.3 M +$12.5 M +52.6% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-14
Q4 2016 -$59 M -$11.3 M +$10.5 M +48.2% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-15
Q3 2016 -$69.4 M -$9.56 M +$7.55 M +44.1% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-15
Q2 2016 -$77 M -$14.4 M -$907 K -6.72% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-15
Q1 2016 -$76.1 M -$23.8 M -$10.3 M -76% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-15
Q4 2015 -$65.8 M -$21.7 M -$7.3 M -50.7% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-16
Q3 2015 -$58.5 M -$17.1 M -$4.97 M -40.9% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-16
Q2 2015 -$53.5 M -$13.5 M -$434 K -3.32% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-16
Q1 2015 -$53.1 M -$13.5 M -$2.36 M -21.2% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-16
Q4 2014 -$50.7 M -$14.4 M +$14.9 M +50.8% Oct 2, 2014 Dec 31, 2014 10-K 2016-03-15
Q3 2014 -$65.6 M -$12.1 M -$1.94 M -19% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-15
Q2 2014 -$63.7 M -$13.1 M -$4.95 M -60.9% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-15
Q1 2014 -$58.7 M -$11.1 M -$2.76 M -32.9% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-15
Q4 2013 -$56 M -$29.3 M -$22.2 M -315% Sep 29, 2013 Dec 31, 2013 10-K 2015-03-11
Q3 2013 -$33.8 M -$10.2 M -$4.26 M -71.6% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-11
Q2 2013 -$29.5 M -$8.12 M -$2.04 M -33.5% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-11
Q1 2013 -$27.5 M -$8.38 M -$2.46 M -41.7% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-11
Q4 2012 -$25 M -$7.06 M -$1.61 M -29.6% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-17
Q3 2012 -$23.4 M -$5.95 M -$1.71 M -40.5% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-17
Q2 2012 -$21.7 M -$6.08 M -$1.1 M -22.1% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-17
Q1 2012 -$20.6 M -$5.92 M -$1.89 M -46.9% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-17
Q4 2011 -$18.7 M -$5.45 M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-18
Q3 2011 -$4.23 M -$1.77 M -72.2% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-18
Q2 2011 -$4.98 M -$2.67 M -115% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-18
Q1 2011 -$4.03 M Jan 1, 2011 Mar 31, 2011 10-K 2013-03-18
Q3 2010 -$2.46 M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-08
Q2 2010 -$2.32 M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.